Seagen Inc.
Combination of CD33 antibody drug conjugates with chemotherapeutic agents
Last updated:
Abstract:
This invention relates to treatment of cancer using a CD33 antibody drug conjugate in combination with chemotherapeutic agents.
Status:
Grant
Type:
Utility
Filling date:
2 Jun 2017
Issue date:
7 Sep 2021